For Members of the LMH Health Medical Staff and Independent Practices:

Monoclonal Antibody Treatment Updates

Below are the communications concerning monoclonal allocations, criteria and referral information. This page is not accessible by the public using site or internet search. Please bookmark this page or use www.lmh.org/mab to access this page directly.

Monoclonal antibody (MAB) infusion order & referral form

8-22-22 | Monoclonal antibody changes

The Federal government has exhausted the supply of Bebtelovimab they purchased for use during the pandemic. Lilly will now make the make the monoclonal available commercially, though it is still under the FDA’s Emergency Use Authorization. At the present time, Lilly does not plan to pursue full approval from the FDA. LMH Health would like to continue to offer monoclonal antibody infusions to qualified patients on a thirty day trial basis, as it has appeared to be effective in preventing qualified COVID patients from becoming ill enough to be admitted to the hospital.

4-8-22 | Limited infusion-based regimens available due to revocation of Sotrovimab EUA

Due to reduced efficacy and BA.2 dominance, the FDA recently revoked the EUA for Sotrovimab eliminating it as a treatment option for COVID-19 infections in patients at high-risk for progression to severe COVID-19 disease. This will limit our available infusion-based regimens for COVID-19 treatment to Bebtelovimab.

3-11-22 | Monoclonal status GREEN

Our current monoclonal status is Tier 1/GREEN, which means we currently have enough supply on hand to infuse 6-10 patients per day for one week. We ask that you continue to remain judicious on referrals to ensure the capacity of the Treatment and Procedure Center is not exceeded.

3-4-22 | Monoclonal status YELLOW

Our current monoclonal status is Tier 2/YELLOW, which means we currently have enough supply on hand to infuse 3-5 patients per day for one week. We ask that you continue to remain judicious on referrals to ensure the capacity of the Treatment and Procedure Center is not exceeded.

2-25-22 | Monoclonal status YELLOW

Our current monoclonal status is Tier 2/YELLOW, which means we currently have enough supply on hand to infuse 3-5 patients per day for one week. We ask that you continue to remain judicious on referrals to ensure the capacity of the Treatment and Procedure Center is not exceeded.

2-11-22 | Monoclonal status YELLOW

Monoclonal allocations continue to fluctuate – currently our status is Tier 2/YELLOW, which means we currently have enough supply on hand to infuse 3-5 patients per day for one week. We ask that you continue to remain judicious on referrals to ensure the capacity of the Treatment and Procedure Center is not exceeded.

2-4-22 | Monoclonal status YELLOW

Monoclonal allocations continue to fluctuate – currently our status is Tier 2/YELLOW, which means we currently have enough supply on hand to infuse 3-5 patients per day for one week. We ask that you continue to remain judicious on referrals to ensure the capacity of the Treatment and Procedure Center is not exceeded.

1-26-22 | Monoclonal status YELLOW

Monoclonal allocations continue to fluctuate – currently our status is Tier 2/YELLOW, which means we currently have enough supply on hand to infuse 3-5 patients per day for one week. We ask that you continue to remain judicious on referrals to ensure the capacity of the Treatment and Procedure Center is not exceeded.

1-12-22 | Monoclonal status RED

LMH Health remains in Tier 3/RED for IV monoclonal antibody (mAB) therapy, as our allocation was only six doses this week. Please note that it is very likely we will exhaust our supply before an allocation can arrive next week. Once this happens, we will announce that we are in Tier 4/BLUE, meaning that no monoclonal antibodies are available. Given the greater than 80% dominance of the Omicron variant, we cannot use the previous two agents (Bamlanivimab/Etesevimab or Casirivimab/Imdevimab).

1-5-22 | Monoclonal status RED

LMH Health has received a limited allocation of monoclonal antibodies (with confirmation from our distributor) and will restart mAb infusions on 1/6/22 in a Red: (Tier 3) status allowing for 3 infusions per day through TPC. In keeping with the current Tier 3 resource state, patients must fulfill standard mAb criteria plus > 4 or more high risk factors. Infusions will continue to occur on a first come, first serve basis and request judicious ordering practices.

12-29-21 - 2:30 p.m. | Monoclonal allocation depleted

The situation surrounding COVID-19 and monoclonal antibodies continues to change at a rapid pace. Due to the enormous number of orders received, we’ve depleted our allocation of monoclonal antibodies and TPC is no longer scheduling appointments, effective immediately. We’ve been informed that HHS is no longer sending two of the three monoclonals to us. We will provide an update next week when we get our allocation of the single monoclonal treatment that is effective against omicron.

If you have questions, please reach out to Dr. Brychel, Caitlin Johnston or Chris Lawrenz.

12-29-21 - 11 a.m. | Treatment & Procedure Center (TPC) status

The Treatment and Procedure Center (TPC) is overwhelmed with orders as the current COVID-19 surge continues. We ask that providers DO NOT share with TPC’s phone number with patients for follow up. It may take 24-48 hours for TPC staff to call the patient for scheduling, so we ask for their patience and yours during this trying time. As the situation continues to evolve, TPC continues to make daily adjustments.

12-28-21 | Monoclonal status update: GREEN

Monoclonal allocations continue to fluctuate—currently, our tier status is GREEN/Tier 1, which means we currently have enough supply on hand to infuse 6-10 patients per day for one week. We ask that you continue to remain judicious on referrals to ensure the capacity of the Treatment and Procedure Center is not exceeded.

12-21-21 | Monoclonal status GREEN

Monoclonal allocations continue to fluctuate—currently, our tier status is GREEN/Tier 1, which means we currently have enough supply on hand to infuse 6-10 patients per day for one week. Read on for details, and please understand that due to the spread of the omicron variant, this continues to be a rapidly-evolving situation.

12-17-21 | Monoclonal shortage plan

Due to the rapidly changing nature of monoclonal allocations within the pandemic, we must prepare for shortages to optimize access for our highest risk patients. Unfortunately, we currently find ourselves within a shortage period and contingency criteria will need to be enacted. Updated information will be communicated every Tuesday to inform what our current status will be for the upcoming week and will be listed as red, yellow, green or blue.

12-10-21 | Monoclonal Antibody Therapy - Weekend Ordering

Due to the sudden interruption in the monoclonal supply chain, BMI and symptom duration criteria have changed to ensure greatest benefit for our highest risk patients is prioritized.

12-03-21 | Monoclonal Antibody Therapy Update

Due to the sudden interruption in the monoclonal supply chain, BMI and symptom duration criteria have changed to ensure greatest benefit for our highest risk patients is prioritized.

11-30-21 | mAb Direct Ordering

This correspondence is to inform you of a significant change in referrals for monoclonal antibody (mAb) infusions for the treatment of mild-to-moderate COVID-19 disease in patients at risk for progression to severe COVID-19 illness. Beginning December 6, 2021, mAb will no longer require a referral and will become directly orderable by each provider.